Vironexis Biotherapeutics Inc.
Clinical trials sponsored by Vironexis Biotherapeutics Inc., explained in plain language.
-
New 'Off-the-Shelf' gene therapy aims to outsmart tough blood cancers
Disease control Recruiting nowThis early-stage study is testing a new, one-time gene therapy called VNX-101 for patients whose B-cell blood cancers have returned or not responded to other treatments. The therapy is designed to help the patient's own immune system continuously fight cancer cells. Researchers w…
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
One-Shot gene therapy trial aims to turn body into Cancer-Fighting factory
Disease control Recruiting nowThis first-in-human trial is testing a new gene therapy called VNX-202 for people with HER2-positive cancers. The therapy uses a single IV infusion to teach the liver to continuously produce cancer-fighting proteins, potentially eliminating the need for repeated treatments. Resea…
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC